NCT03042416View on ClinicalTrials.gov

18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety

PHASE3CompletedINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

June 29, 2017

Primary Completion Date

March 5, 2021

Study Completion Date

June 2, 2021

Conditions
Congenital HyperinsulinismNeuroblastomaNeuroendocrine TumorsParkinson DiseaseBrain Glioma
Interventions
DRUG

18F-DOPA

18F-DOPA intravenous injection single dose

Trial Locations (1)

T6G2B7

University of Alberta Hospital, Edmonton

All Listed Sponsors
collaborator

Alberta Health services

OTHER

lead

University of Alberta

OTHER

NCT03042416 - 18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety | Biotech Hunter | Biotech Hunter